A Multicenter, Open-Label Immunogenicity and Safety Study of Natalizumab High Titer Material (BG00002-E) in Subjects With Relapsing Forms of Multiple Sclerosis.
Phase of Trial: Phase II
Latest Information Update: 04 Jun 2015
At a glance
- Drugs Natalizumab (Primary)
- Indications Multiple sclerosis
- Focus Adverse reactions
- Sponsors Biogen Idec
- 29 Jan 2008 Status changed from recruiting to completed.
- 27 Aug 2007 New trial record.